Search alternatives:
significant side » significant sex (Expand Search), significant burden (Expand Search), significant source (Expand Search)
side decrease » sizes decrease (Expand Search), fid decreased (Expand Search), we decrease (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
Showing 921 - 940 results of 3,861 for search '(( significant side decrease ) OR ( significant ((step decrease) OR (mean decrease)) ))', query time: 0.49s Refine Results
  1. 921
    Sex differences and percentage change trends in smoking-attributable RA burden from 1990 to 2021.

    Sex differences and percentage change trends in smoking-attributable RA burden from 1990 to 2021. by Kaibin Lin (9911049)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 922
    Age-standardised rates (per 100,000 population) of rheumatoid arthritis burden attributable to smoking in 1990 and 2021, and trends from 1990 to 2021, by GBD Super-Region.

    Age-standardised rates (per 100,000 population) of rheumatoid arthritis burden attributable to smoking in 1990 and 2021, and trends from 1990 to 2021, by GBD Super-Region. by Kaibin Lin (9911049)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 923
    Minimal dataset for the study.

    Minimal dataset for the study. by Kaibin Lin (9911049)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 924
    Burden of RA attributable to smoking in 2021 across 204 countries and territories.

    Burden of RA attributable to smoking in 2021 across 204 countries and territories. by Kaibin Lin (9911049)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 925
    Sex and age differences in smoking-attributable RA burden in 2021.

    Sex and age differences in smoking-attributable RA burden in 2021. by Kaibin Lin (9911049)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 926
    Smoking-Attributable RA Burden from 2000 to 2021: Global Temporal Trends and Regional Differences in Smoking Prevalence and Burden Indicators.

    Smoking-Attributable RA Burden from 2000 to 2021: Global Temporal Trends and Regional Differences in Smoking Prevalence and Burden Indicators. by Kaibin Lin (9911049)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 927
    Relationship between SDI and smoking-attributable RA burden.

    Relationship between SDI and smoking-attributable RA burden. by Kaibin Lin (9911049)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 928
    a. Positive ion mode, significant difference, metabolite level clustering heat map (A), mild PTOA group VS severe PTOA group, (B) mild PTOA group VS normal group, (C) severe PTOA group VS normal group. b. Negative ion pattern significant difference metabolite level clustering heat map (A) Mild PTOA group VS severe PTOA group (B) Mild PTOA group VS normal group (C) Severe PTOA group VS normal group.

    a. Positive ion mode, significant difference, metabolite level clustering heat map (A), mild PTOA group VS severe PTOA group, (B) mild PTOA group VS normal group, (C) severe PTOA g... by Peng-fei Han (694841)

    Published 2025
    Save to List
    Saved in:
  9. 929
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  10. 930
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  11. 931
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  12. 932
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  13. 933
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  14. 934
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  15. 935
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  16. 936
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  17. 937
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  18. 938
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  19. 939
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  20. 940
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:

Search Tools: